Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press14910.17650/1726-9776-2011-7-2-216-241DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряEFFICIENCY OF BEAM RADIOTHERAPY FOR NON-MUSCLE-INVASIVE BLADDER CANCERЭФФЕКТИВНОСТЬ ДИСТАНЦИОННОЙ ЛУЧЕВОЙ ТЕРАПИИ НЕМЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯSafiullinK. N.СафиуллинК. Н.
Russian Federation
safiulin@mrrc.obninsk.ruGumenetskayaYu. V.ГуменецкаяЮ. В.
Russian Federation
safiulin@mrrc.obninsk.ruKaryakinO. B.КарякинО. Б.
Russian Federation
safiulin@mrrc.obninsk.ruMedical Radiology Research Center, Ministry of Health and Social Development of Russia, ObninskФГБУ МРНЦ Минздравсоцразвития России, Обнинск300620117235382907201429072014https://oncourology.abvpress.ru/oncur/article/view/149

Objective: to evaluate the efficiency of beam radiotherapy (BRT) in patients with non-muscle-invasive bladder cancer (NMIBC).

Subjects and methods. The data on 40 patients diagnosed as having stage T1 NMIBC, who had been treated at the Medical Radiology Center in 1990 to 2009, were studied. Of them, 75% were aged < 70 years. They all had verified transitional cell carcinoma: G1 in 11 (27.5%) patients; G2 in 12 (30%), and G3 in 17 (42.5%). Multifocal tumor growth (T1m) was found in 22 (55%); the largest tumor exceeded 3 cm in 31 (77.5%). More than half (60%) of the patients had clinically significant concomitant diseases. Three (7.5%) had a history of treated malignancy. The mean follow-up of the patients was 58.6 months.

Results. Survival at 60 months follow-up was 67.9 ± 8.0%. Three (7.5 %) patients died at 21–42 months follow-up. Five-year relapse-free survival was 50.0 ± 8.5%. Seven (17.5 %) patients were withdrawn at 5 to 99 months follow-up (mean 34.7 months). Four (10 %) patients died from disease progression at 21 to 143 months follow-up. After radiotherapy to the bladder area, 17 (42.5 %) patients were diagnosed as having more than 50 % tumor regression, which permitted transurethral resection of a residual tumor. The frequency and degree of radiation reactions were estimated. Acute radiation cystitis was diagnosed in 11 (27.5 %) patients and rectitis was found in 6 (15.0 %). Radiation reactions were not a reason for forced treatment discontinuation. Grade I-II late radiation cystitis (RTOG/EORTC) was diagnosed in 9 (22.5 %) patients.

Conclusion. The efficiency of BRT in patients with NMIBC who had refused surgical treatment or had contraindications to it was confirmed during the study. BRT could preserve the functioning bladder in 97.5 % of cases and remove the residual tumor in 42.5 %. Radiation reactions were not a reason for forced treatment interruption.

non-muscle-invasive bladder cancerbeam radiotherapysurvivalнемышечно-инвазивный рак мочевого пузырядистанционная лучевая терапиявыживаемость1. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В Старинского, Г.В. Петровой. М., 2010.Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В Старинского, Г.В. Петровой. М., 2010.2. Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Фотодинамическая диагностика и флуоресцентная спектроскопия при поверхностном раке мочевого пузыря. Онкоурология 2009;4:41–6.Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Фотодинамическая диагностика и флуоресцентная спектроскопия при поверхностном раке мочевого пузыря. Онкоурология 2009;4:41–6.3. Brausi M., Collette L., Kurth K. et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523–31.Brausi M., Collette L., Kurth K. et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523–31.4. Ткачев С.И., Фигурин К.М., Медведев С.В. Лучевая терапия больных раком мочевого пузыря. Онкоурология 2006;3:5–11.Ткачев С.И., Фигурин К.М., Медведев С.В. Лучевая терапия больных раком мочевого пузыря. Онкоурология 2006;3:5–11.5. Мартов А.Г., Сысоев П.А. Лечение поверхностного рака мочевого пузыря. Урология 2000;2:44–9.Мартов А.Г., Сысоев П.А. Лечение поверхностного рака мочевого пузыря. Урология 2000;2:44–9.6. Weef-Messing V., Menon R.S., Hop W.C.J. Cancer of the urinary bladder category T2, T3 (NM0) treated by interstitial radium implant: Second report. Int J Radiat Oncol Biol Phys 1983;9:481–5.Weef-Messing V., Menon R.S., Hop W.C.J. Cancer of the urinary bladder category T2, T3 (NM0) treated by interstitial radium implant: Second report. Int J Radiat Oncol Biol Phys 1983;9:481–5.7. Leung H.Y., Griffiths T.R.L., Neal D.E. Bladder cancer. Postgrad Med J 1996;72:719–24.Leung H.Y., Griffiths T.R.L., Neal D.E. Bladder cancer. Postgrad Med J 1996;72:719–24.8. Яненко Э.К., Кульга Л.Г. Актуальные вопросы лечения онкоурологических заболеваний: Материалы 2-й Всероссийской науч. конф. с участием стран СНГ. Обнинск, 1997; с. 87–8.Яненко Э.К., Кульга Л.Г. Актуальные вопросы лечения онкоурологических заболеваний: Материалы 2-й Всероссийской науч. конф. с участием стран СНГ. Обнинск, 1997; с. 87–8.9. Матвеев В.Б., Волкова М.И., Фигурин К.М., Петерс М.В. Спасительная цистэктомия у больных переходно-клеточным раком мочевого пузыря. Онкоурология 2009;1:27–31.Матвеев В.Б., Волкова М.И., Фигурин К.М., Петерс М.В. Спасительная цистэктомия у больных переходно-клеточным раком мочевого пузыря. Онкоурология 2009;1:27–31.10. Симонов В.Я., Варенцов Г.И. Эндоскопическая хирургия и дистанционная литотрипсия. Под ред. В.Я. Симонова. М., 1992; с. 71–81.Симонов В.Я., Варенцов Г.И. Эндоскопическая хирургия и дистанционная литотрипсия. Под ред. В.Я. Симонова. М., 1992; с. 71–81.11. Матвеев Б.П., Фигурин К.М. Всероссийское общество урологов. Пленум: Тезисы докладов. Кемерово, 1995; с. 175–87.Матвеев Б.П., Фигурин К.М. Всероссийское общество урологов. Пленум: Тезисы докладов. Кемерово, 1995; с. 175–87.12. Duncan W., Quilry D.M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299–310.Duncan W., Quilry D.M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299–310.13. Nieuwenhuijzen J.A., Horenblas S., Meinhardt W. et al. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Intern 2004;94(6):793–7.Nieuwenhuijzen J.A., Horenblas S., Meinhardt W. et al. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Intern 2004;94(6):793–7.14. Weiss C., Wolze C., Engehausen D.G. et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006;24(15):2318–24.Weiss C., Wolze C., Engehausen D.G. et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006;24(15):2318–24.15. Клинические рекомендации Европейской ассоциации урологов. М., 2010; с. 39–40.Клинические рекомендации Европейской ассоциации урологов. М., 2010; с. 39–40.